Rational Design of Novel Therapies for Pantothenate Kinase-Associated Neurodegeneration.
clinical rating scale
neurodegeneration with brain iron accumulation
pantothenate kinase-associated neurodegeneration
translational therapy
treatment
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
09
03
2021
received:
01
12
2020
accepted:
23
04
2021
pubmed:
19
5
2021
medline:
14
10
2021
entrez:
18
5
2021
Statut:
ppublish
Résumé
This review highlights the recent scientific advances that have enabled rational design of novel clinical trials for pantothenate kinase-associated neurodegeneration (PKAN), a rare autosomal recessive neurogenetic disorder associated with progressive neurodegenerative changes and functional impairment. PKAN is caused by genetic variants in the PANK2 gene that result in dysfunction in pantothenate kinase 2 (PANK2) enzyme activity, with consequent disruption of coenzyme A (CoA) synthesis, and subsequent accumulation of brain iron. The clinical phenotype is varied and may include dystonia, rigidity, bradykinesia, postural instability, spasticity, loss of ambulation and ability to communicate, feeding difficulties, psychiatric issues, and cognitive and visual impairment. There are several symptom-targeted treatments, but these do not provide sustained benefit as the disorder progresses. A detailed understanding of the molecular and biochemical pathogenesis of PKAN has opened the door for the design of novel rationally designed therapeutics that target the underlying mechanisms. Two large double-blind phase 3 clinical trials have been completed for deferiprone (an iron chelation treatment) and fosmetpantotenate (precursor replacement therapy). A pilot open-label trial of pantethine as a potential precursor replacement strategy has also been completed, and a trial of 4-phosphopantetheine has begun enrollment. Several other compounds have been evaluated in pre-clinical studies, and additional clinical trials may be anticipated. Experience with these trials has encouraged a critical evaluation of optimal trial designs, as well as the development of PKAN-specific measures to monitor outcomes. PKAN provides a valuable example for understanding targeted drug development and clinical trial design for rare disorders. © 2021 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
This review highlights the recent scientific advances that have enabled rational design of novel clinical trials for pantothenate kinase-associated neurodegeneration (PKAN), a rare autosomal recessive neurogenetic disorder associated with progressive neurodegenerative changes and functional impairment. PKAN is caused by genetic variants in the PANK2 gene that result in dysfunction in pantothenate kinase 2 (PANK2) enzyme activity, with consequent disruption of coenzyme A (CoA) synthesis, and subsequent accumulation of brain iron. The clinical phenotype is varied and may include dystonia, rigidity, bradykinesia, postural instability, spasticity, loss of ambulation and ability to communicate, feeding difficulties, psychiatric issues, and cognitive and visual impairment. There are several symptom-targeted treatments, but these do not provide sustained benefit as the disorder progresses.
OBJECTIVES
A detailed understanding of the molecular and biochemical pathogenesis of PKAN has opened the door for the design of novel rationally designed therapeutics that target the underlying mechanisms.
METHODS
Two large double-blind phase 3 clinical trials have been completed for deferiprone (an iron chelation treatment) and fosmetpantotenate (precursor replacement therapy). A pilot open-label trial of pantethine as a potential precursor replacement strategy has also been completed, and a trial of 4-phosphopantetheine has begun enrollment. Several other compounds have been evaluated in pre-clinical studies, and additional clinical trials may be anticipated.
CONCLUSIONS
Experience with these trials has encouraged a critical evaluation of optimal trial designs, as well as the development of PKAN-specific measures to monitor outcomes. PKAN provides a valuable example for understanding targeted drug development and clinical trial design for rare disorders. © 2021 International Parkinson and Movement Disorder Society.
Substances chimiques
Iron
E1UOL152H7
Phosphotransferases (Alcohol Group Acceptor)
EC 2.7.1.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2005-2016Subventions
Organisme : NINDS NIH HHS
ID : U54 NS116025
Pays : United States
Informations de copyright
© 2021 International Parkinson and Movement Disorder Society.
Références
Di Meo I, Carecchio M, Tiranti V. Inborn errors of coenzyme a metabolism and neurodegeneration. J Inherit Metab Dis 2019;42:49-56.
Hayflick SJ, Kurian MA, Hogarth P. Neurodegeneration with brain iron accumulation. In: Geschwind DH, Paulson HL, Klein C, eds. Handbook of Clinical Neurology. Amsterdam: Elsevier BV; 2018:293-305.
Brezavar D, Bonnen PE. Incidence of PKAN determined by bioinformatic and population-based analysis of ~140,000 humans. Mol Genet Metab 2019;128:463-469.
Chang X, Zhang J, Jiang Y, Wang J, Wu Y. Natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration. CNS Neurosci Ther 2020;26:754-761.
Lee JH, Park J, Ryu HS, et al. Clinical heterogeneity of atypical pantothenate kinase-associated neurodegeneration in Koreans. J Mov Disord 2016;9:20-27.
Hartig MB, Hortnagel K, Garavaglia B, et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 2006;59:248-256.
Hogarth P, Kurian MA, Gregory A, et al. Consensus clinical management guideline for pantothenate kinase-associated neurodegeneration (PKAN). Mol Genet Metab 2017;120:278-287.
Zorzi G, Nardocci N. Therapeutic advances in neurodegeneration with brain iron accumulation. Int Rev Neurobiol 2013;110:153-164.
De Vloo P, Lee DJ, Dallapiazza RF, et al. Deep brain stimulation for pantothenate kinase-associated neurodegeneration: a meta-analysis. Mov Disord 2019;34:264-273.
Ceccatelli Berti C, Gilea AI, De Gregorio MA, Goffrini P. Exploring yeast as a study model of pantothenate kinase-associated neurodegeneration and for the identification of therapeutic compounds. Int J Mol Sci 2020;22:293.
ClinicalTrials.gov. A two-arm efficacy and safety study of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN). 2017.
Klopstock T, Tricta F, Neumayr L, et al. Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study. Lancet Neurol 2019;18:631-642.
Klopstock T, Videnovic A, Turid-Bischoff A, et al. Fosmetpantotentate randomized controlled trial in pantothenate kinase-associated neurodegeneration. Mov Disord 2020. https://doi.org/10.1002/mds.28392.
Chang X, Zhang J, Jiang Y, Yao B, Wang J, Wu Y. Pilot trial on the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration: a single-arm, open-label study. Orphanet J Rare Dis 2020;15:248.
Srinivasan B, Baratashvili M, van der Zwaag M, et al. Extracellular 4′-phosphopantetheine is a source for intracellular coenzyme A synthesis. Nat Chem Biol 2015;11:784-792.
Jeong SY, Hogarth P, Placzek A, et al. 4'-Phosphopantetheine corrects CoA, iron, and dopamine metabolic defects in mammalian models of PKAN. EMBO Mol Med 2019;11:e10489.
Di Meo I, Colombelli C, Srinivasan B, et al. Acetyl-4′-phosphopantetheine is stable in serum and prevents phenotypes induced by pantothenate kinase deficiency. Sci Rep 2017;7:11260.
Álvarez-Córdoba M, Fernandez Khoury AF, Villanueva-Paz M, et al. Pantothenate rescues iron accumulation in pantothenate kinase-associated neurodegeneration depending on the type of mutation. Mol Neurobiol 2019;56:3638-3656.
Sharma LK, Subramanian C, Yun M-K, et al. A therapeutic approach to pantothenate kinase associated neurodegeneration. Nat Commun 2018;9:4399.
Zhang YM, Rock CO, Jackowski S. Biochemical properties of human pantothenate kinase 2 isoforms and mutations linked to pantothenate kinase-associated neurodegeneration. J Biol Chem 2006;281(1):107-114.
Pietrocola F, Galluzzi L, Bravo-San Pedro JM, Madeo F, Kroemer G. Acetyl coenzyme A: a central metabolite and second messenger. Cell Metab 2015;21:805-821.
Fisher EMC, Bannerman DM. Mouse models of neurodegeneration: know your question, know your mouse. Sci Transl Med 2019;11:493.
Orellana DI, Santambrogio P, Rubio A, et al. Coenzyme a corrects pathological defects in human neurons of PANK2-associated neurodegeneration. EMBO Mol Med 2016;8:1197-1211.
Poli M, Derosas M, Luscieti S, et al. Pantothenate kinase-2 (Pank2) silencing causes cell growth reduction, cell-specific ferroportin upregulation and iron deregulation. Neurobiol Dis 2010;39:204-210.
Drecourt A, Babdor J, Dussiot M, et al. Impaired transferrin receptor palmitoylation and recycling in neurodegeneration with brain iron accumulation. Am J Hum Genet 2018;102:266-277.
Arber C, Angelova PR, Wiethoff S, et al. iPSC-derived neuronal models of PANK2-associated neurodegeneration reveal mitochondrial dysfunction contributing to early disease. PloS One 2017;12(9):e0184104.
Berti CC, Gilea AI, De Gregorio MA, Goffrini P. Exploring yeast as a study model of pantothenate kinase-associated neurodegeneration and for the identification of therapeutic compounds. Int J Mol Sci 2021;22:293.
Rana A, Seinen E, Siudeja K, et al. Pantethine rescues a Drosophila model for pantothenate kinase-associated neurodegeneration. Proc Natl Acad Sci U S A 2010;107:6988-6993.
Siudeja K, Srinivasan B, Xu L, et al. Impaired coenzyme a metabolism affects histone and tubulin acetylation in drosophila and human cell models of pantothenate kinase associated neurodegeneration. EMBO Mol Med 2011;3:755-766.
Bosveld F, Rana A, van der Wouden PE, et al. De novo CoA biosynthesis is required to maintain DNA integrity during development of the drosophila nervous system. Hum Mol Genet 2008;17:2058-2069.
Afshar K, Gonczy P, Dinardo S, Wasserman SA. Fumble encodes a pantothenate kinase homolog required for proper mitosis and meiosis in Drosophila melanogaster. Genetics 2001;157:1267-1276.
Zizioli D, Tiso N, Guglielmi A, et al. Knock-down of pantothenate kinase 2 severely affects the development of the nervous and vascular system in zebrafish, providing new insights into PKAN disease. Neurobiol Dis 2016;85:35-48.
Pandey V, Varun P, Turm H, et al. A new in vivo model of pantothenate kinase-associated neurodegeneration reveals a surprising role for transcriptional regulation in pathogenesis. Front Cell Neurosci 2013;7:146.
Nakamura T, Pluskal T, Nakaseko Y, Yanagida M. Impaired coenzyme A synthesis in fission yeast causes defective mitosis, quiescence-exit failure, histone hypoacetylation and fragile DNA. Open Biol 2012;2:120117.
Kuo YM, Duncan JL, Westaway SK, et al. Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Hum Mol Genet 2005;14:49-57.
Kuo YM, Hayflick SJ, Gitschier J. Deprivation of pantothenic acid elicits a movement disorder and azoospermia in a mouse model of pantothenate kinase-associated neurodegeneration. J Inherit Metab Dis 2007;30:310-317.
Brunetti D, Dusi S, Morbin M, et al. Pantothenate kinase-associated neurodegeneration: altered mitochondria membrane potential and defective respiration in Pank2 knock-out mouse model. Hum Mol Genet 2012;21:5294-5305.
Subramanian C, Yao J, Frank MW, Rock CO, Jackowski S. A pantothenate kinase-deficient mouse model reveals a gene expression program associated with brain coenzyme a reduction. Biochim Biophys Acta Mol Basis Dis 2020;1866:165663.
Dawson TM, Golde TE, Lagier-Tourenne C. Animal models of neurodegenerative diseases. Nat Neurosci 2018;21:1370-1379.
Leonardi R, Rock CO, Jackowski S, Zhang YM. Activation of human mitochondrial pantothenate kinase 2 by palmitoylcarnitine. Proc Natl Acad Sci U S A 2007;104:1494-1499.
Alfonso-Pecchio A, Garcia M, Leonardi R, Jackowski S. Compartmentalization of mammalian pantothenate kinases. PloS One 2012;7:e49509.
Garcia M, Leonardi R, Zhang YM, Rehg JE, Jackowski S. Germline deletion of pantothenate kinases 1 and 2 reveals the key roles for CoA in postnatal metabolism. PloS One 2012;7:e40871.
Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 2014;21:195-210.
Dusek P, Schneider SA, Aaseth J. Iron chelation in the treatment of neurodegenerative diseases. J Trace Elem Med Biol 2016;38:81-92.
Kakhlon O, Breuer W, Munnich A, Cabantchik ZI. Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. Can J Physiol Pharmacol 2010;88:187-196.
Sohn YS, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 2008;111:1690-1699.
Rohani M, Razmeh S, Shahidi GA, Alizadeh E, Orooji M. A pilot trial of deferiprone in pantothenate kinase-associated neurodegeneration patients. Neurol Int 2017;9(4):7279.
Cossu G, Abbruzzese G, Matta G, et al. Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up. Parkinsonism Relat Disord 2014;20:651-654.
Abbruzzese G, Cossu G, Balocco M, et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011;96:1708-1711.
Zano SP, Pate C, Frank M, Rock CO, Jackowski S. Correction of a genetic deficiency in pantothenate kinase 1 using phosphopantothenate replacement therapy. Mol Genet Metab 2015;116:281-288.
Balibar CJ, Hollis-Symynkywicz MF, Tao J. Pantethine rescues phosphopantothenoylcysteine synthetase and phosphopantothenoylcysteine decarboxylase deficiency in Escherichia coli but not in Pseudomonas aeruginosa. J Bacteriol 2011;193:3304-3312.
Elbaum D, Beconi MG, Monteagudo E, et al. Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: mechanism of action and efficacy in nonclinical models. PloS One 2018;13:e0192028.
Christou YP, Tanteles GA, Kkolou E, et al. Open-label fosmetpantotenate, a phosphopantothenate replacement therapy in a single patient with atypical PKAN. Case Rep Neurol Med 2017;2017:3247034.
Roa P, Stoeter P, Perez-Then E, Santana M, Marshall RD. A pilot study of a potential phosphopantothenate replacement therapy in 2 patients with pantothenate kinase-associated neurodegeneration. Int J Rare Dis Orphan Drugs 2017;2(2):1006.
Marshall RD, Collins A, Escolar ML, et al. A scale to assess activities of daily living in pantothenate kinase-associated neurodegeneration. Mov Disord Clin Pract 2019;6:139-149.
Brunetti D, Dusi S, Giordano C, et al. Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model. Brain 2014;137:57-68.
Hitchcock SA, Pennington LD. Structure-brain exposure relationships. J Med Chem 2006;49:7559-7583.
Rankovic Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J Med Chem 2015;58:2584-2608.
Subramanian C, Yun MK, Yao J, et al. Allosteric regulation of mammalian pantothenate kinase. J Biol Chem 2016;291:22302-22314.
Tomić A, Petrović I, Svetel M, Dobričić V, Dragašević Mišković N, Kostic VS. Pattern of disease progression in atypical form of pantothenate-kinase-associated neurodegeneration (PKAN) - prospective study. Parkinsonism Relat Disord 2015;21:521-524.
Freeman K, Gregory A, Turner A, Blasco P, Hogarth P, Hayflick S. Intellectual and adaptive behaviour functioning in pantothenate kinase-associated neurodegeneration. J Intell Disab Res 2007;51:417-426.
Marelli C, Piacentini S, Garavaglia B, Girotti F, Albanese A. Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegeneration. Mov Disord 2005;20:208-212.
Darling A, Tello C, Marti MJ, et al. Clinical rating scale for pantothenate kinase-associated neurodegeneration: a pilot study. Mov Disord 2017;32:1620-1630.
Barry MJ, VanSwearingen JM, Albright AL. Reliability and responsiveness of the Barry-Albright dystonia scale. Dev Med Child Neurol 1999;41:404-411.
Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985;35:73-77.
Ottenbacher KJ, Hsu Y, Granger CV, Fiedler RC. The reliability of the functional independence measure: a quantitative review. Arch Phys Med Rehabil 1996;77:1226-1232.
Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.